Abstract
Methods Patients: MO group: 48 patients (40 women and 8 men) diagnosed of MO with an age of 46.9± 7.9. Control group: 19 subjects without overweight and with normal analytical data and normal ultrasound scan of the liver. The following parameters were measured: A.Clinical data: Age, sex, weight, height, abdominal and hip perimeters, Body Mass Index (BMI), clinical history and pharmacological treatment, Metabolic Syndrome, morfometry and haematic chemistry, Insulin Resistance (HOMA) and viral markers. B Immunomodulators: (Leptin, Adiponectin, CK18Asp396 (CK18), Interleukin-6 (IL-6), aldosterone and rennin). C Histological analysis was performed after obtaining hepatic tissue during surgery for MO. The NAFLD Score was calculated: Steatosis Degree, Fibrosis, Inflammation, hepatocyte lesions and other injuries).
Highlights
We find higher values of cGMP in plasma from patients with Nonalcoholic Fatty Liver Disease (NAFLD) than in the control group (F =2.35; p
According to the clinical and analytical data studied, the cGMP level in plasma was higher according to the waist to hip ratio (p
There is an alteration in cGMP metabolism in NAFLD in patients with morbid obesity
Summary
From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Halle, Germany. Aims To study cGMP metabolism in Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Morbid Obesity (MO)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
